Skip to main content
SpringerLink
Log in

Electrocardiographic and echocardiographic findings in muscular dystrophy patients with heart failure

  • Short Communication
  • Published:
Heart and Vessels Aims and scope Submit manuscript

Abstract

Cardiac involvement in muscular dystrophy (MD) is known to cause heart failure (HF). However, little is known about the differences in electrocardiographic and echocardiographic findings between MD patients with and without the experience of hospitalization for HF. We retrospectively identified 95 MD patients (mean age at diagnosis of MD 41.1 ± 18.7 years; males 64.2%), including nine (9.4%) patients who were hospitalized for HF (the HF group) and 86 (90.6%) patients who were not (the non-HF group) during the follow-up period (16.7 ± 12.2 years). The HF group had a significantly wider QRS duration (126.0 ± 37.6 vs. 98.1 ± 16.7 ms, p < 0.001) and QTc interval (454.6 ± 50.5 vs. 409.5 ± 23.6 ms, p < 0.001) at the time of HF hospitalization than the non-HF group. The HF group also had a significantly lower left ventricular (LV) ejection fraction (35.4 ± 19.2 vs. 62.5 ± 11.3%, p < 0.001) and significantly larger diastolic LV dimension (64 ± 2 vs. 45 ± 1 mm, p < 0.001) and left atrial diameter (38 ± 12 vs. 29 ± 6 mm, p = 0.003) at the time of HF hospitalization than the non-HF group. In the HF group, the QRS duration was significantly wider at the time of HF hospitalization than at the initial electrocardiogram before the development of HF (129.8 ± 30.7 vs. 119.0 ± 33.3 ms, p = 0.018). This study suggests that HF occurs in MD patients with electrocardiographic and echocardiographic abnormalities. Early recognition of abnormal findings during a regular electrocardiographic or echocardiographic follow-up may be useful for identifying cardiac involvement in MD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Kamdar F, Garry DJ (2016) Dystrophin-deficient cardiomyopathy. J Am Coll Cardiol 67:2533–2546

    Article  CAS  Google Scholar 

  2. Emery AE (2002) The muscular dystrophies. Lancet 359:687–695

    Article  CAS  Google Scholar 

  3. Spurney CF (2011) Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 44:8–19

    Article  Google Scholar 

  4. Fayssoil A, Ogna A, Chaffaut C, Chevret S, Guimaraes-Costa R, Leturcq F, Wahbi K, Prigent H, Lofaso F, Nardi O, Clair B, Behin A, Stojkovic T, Laforet P, Orlikowski D, Annane D (2016) Natural history of cardiac and respiratory involvement, prognosis and predictive factors for long-term survival in adult patients with limb girdle muscular dystrophies type 2C and 2D. PLoS One 11:e0153095

    Article  Google Scholar 

  5. Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S (2011) A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku 51:743–750

    Article  Google Scholar 

  6. Kimura K, Takenaka K, Ebihara A, Uno K, Morita H, Nakajima T, Ozawa T, Aida I, Yonemochi Y, Higuchi S, Motouoshi Y, Mikata T, Uchida I, Ishihara T, Komori T, Kitao R, Nagata T, Takeda S, Yatomi Y, Nagai R, Komuro I (2013) Prognostic impact of left ventricular noncompaction in patients with Duchenne/Becker muscular dystrophy—prospective multicenter cohort study. Int J Cardiol 168:1900–1904

    Article  Google Scholar 

  7. Kimura K, Morita H, Nakamura A, Takenaka K, Daimon M (2016) Therapeutic strategy for heart failure in becker muscular dystrophy. Int Heart J 57:527–529

    Article  CAS  Google Scholar 

  8. Japanese Society of neurology (2014) Practical guideline for Duchenne muscular dystrophy (DMD) 2014. Nannkodo, pp 1–200

  9. Nieminen MS, Harjola VP (2005) Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 96:5G–10G

    Article  Google Scholar 

  10. Templin C, Ghadri JR, Diekmann J, Napp LC, Bataiosu DR, Jaguszewski M, Cammann VL, Sarcon A, Geyer V, Neumann CA, Seifert B, Hellermann J, Schwyzer M, Eisenhardt K, Jenewein J, Franke J, Katus HA, Burgdorf C, Schunkert H, Moller C, Thiele H, Bauersachs J, Tschope C, Schultheiss HP, Laney CA, Rajan L, Michels G, Pfister R, Ukena C, Bohm M, Erbel R, Cuneo A, Kuck KH, Jacobshagen C, Hasenfuss G, Karakas M, Koenig W, Rottbauer W, Said SM, Braun-Dullaeus RC, Cuculi F, Banning A, Fischer TA, Vasankari T, Airaksinen KEJ, Fijalkowski M, Rynkiewicz A, Pawlak M, Opolski G, Dworakowski R, MacCarthy P, Kaiser C, Osswald S, Galiuto L, Crea F, Dichtl W, Frantz WM, Empen K, Felix SB, Delmas C, Lairez O, Erne P, Bax JJ, Ford I, Ruschitzka F, Prasad A, Luscher TF (2015) Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med 373:929–938

    Article  CAS  Google Scholar 

  11. JCS Joint Working Group (2013) Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS 2011). Circ J 77:249–274

    Article  Google Scholar 

  12. Ilkhanoff L, Liu K, Ning H, Nazarian S, Bluemke D, Soliman E, Lloyd-Jones D (2012) Association of QRS duration with left ventricular structure and function and risk of heart failure in middle-aged and older adults: the multi-ethnic study of atherosclerosis (MESA). Eur J Heart Fail 14:1285–1292

    Article  Google Scholar 

  13. Yamada T, Shimonagata T, Misaki N, Asai M, Makino N, Kioka H, Tamaki S, Fukunami M (2004) Usefulness of spatial dispersion of QRS duration in predicting mortality in patients with mild to moderate chronic heart failure. Am J Cardiol 94:960–963

    Article  Google Scholar 

  14. Yamaguchi T, Yoshikawa T, Isogai T, Miyamoto T, Maekawa Y, Ueda T, Sakata K, Murakami T, Yamamoto T, Nagao K, Takayama M (2016) Predictive value of QRS duration at admission for in-hospital clinical outcome of Takotsubo cardiomyopathy. Circ J 81:62–68

    Article  Google Scholar 

  15. Cantor AA, Goldfarb B, Ilia R (2000) QRS prolongation: a sensitive marker of ischemia during percutaneous transluminal coronary angioplasty. Catheter Cardiovasc interv 50:177–183

    Article  CAS  Google Scholar 

  16. Gilmour RF Jr, Evans JJ, Zipes DP (1984) Purkinje-muscle coupling and endocardial response to hyperkalemia, hypoxia, and acidosis. Am J Physiol 247:H303–H311

    PubMed  Google Scholar 

  17. Finsterer J, Stollberger C (2008) Cardiac involvement in Becker muscular dystrophy. Can J Cardiol 24:786–792

    Article  Google Scholar 

  18. Orlov YS, Brodsky MA, Allen BJ, Ott RA, Orlov MV, Jay CA (1994) Cardiac manifestations and their management in Becker’s muscular dystrophy. Am Heart J 128:193–196

    Article  CAS  Google Scholar 

  19. Angelini C, Fanin M, Freda MP, Martinello F, Miorin M, Melacini P, Siciliano G, Pegoraro E, Rosa M, Danieli GA (1996) Prognostic factors in mild dystrophinopathies. J Neurol Sci 142:70–78

    Article  CAS  Google Scholar 

  20. Rapezzi C, Leone O, Biagini E, Coccolo F (2007) Echocardiographic clues to diagnosis of dystrophin related dilated cardiomyopathy. Heart 93:10

    Article  CAS  Google Scholar 

  21. Mori-Yoshimura M, Segawa K, Minami N, Oya Y, Komaki H, Nonaka I, Nishino I, Murata M (2017) Cardiopulmonary dysfunction in patients with limb-girdle muscular dystrophy 2A. Muscle Nerve 55:465–469

    Article  CAS  Google Scholar 

  22. Groen EJ, Charlton R, Barresi R, Anderson LV, Eagle M, Hudson J, Koref MS, Straub V, Bushby KM (2007) Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 130:3237–3249

    Article  Google Scholar 

  23. Nigro G, Comi LI, Politano L, Bain RJ (1990) The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 26:271–2717

    Article  CAS  Google Scholar 

  24. Spurney C, Shimizu R, Morgenroth LP, Hache LP, Kolski H, Gordish-Dressman H, Clemens PR, The CINRG Investigators (2014) Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle Nerve 50:250–256

    Article  Google Scholar 

  25. JCS Joint Working Group (2013) Guidelines for treatment of acute heart failure (JCS 2011). Circ J 77:2157–2201

    Article  Google Scholar 

  26. Bonilla-Palomas JL, Gamez-Lopez AL, Moreno-Conde M, Lopez-Ibanez MC, Anguita-Sanchez M, Gallego de la Sacristana A, Garcia-Catalan F, Villar-Raez A (2014) Hypoalbuminemia in acute heart failure patients: causes and its impact on hospital and long-term mortality. J Card Fail 20:350–358

    Article  CAS  Google Scholar 

  27. Takagi K, Sato N, Ishihara S, Sone M, Tokuyama H, Nakama K, Omote T, Kikuchi A, Ishikawa M, Amitani K, Takahashi N, Maruyama Y, Imura H, Shimizu W (2017) Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria. Heart Vessels. https://doi.org/10.1007/s00380-017-1066-4

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ogata H, Ishikawa Y, Ishikawa Y, Minami R (2009) Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 53:72–78

    Article  Google Scholar 

  29. Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD (2012) Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 110:98–102

    Article  CAS  Google Scholar 

  30. Rhodes J, Margossian R, Darras BT, Colan SD, Jenkins KJ, Geva T, Powell AJ (2008) Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 29:343–351

    Article  CAS  Google Scholar 

  31. De Benedittis G, Rosa GD, D’Ettorre E, Piscitelli P, Distante A, de Gregorio C (2016) Effect of Ivabradine in dilated cardiomyopathy from Duchenne muscular dystrophy: a chance for slowing progression of heart failure? Int J Cardiol 223:286–288

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Cardiology, Tokyo Metropolitan Tama Medical Center, 2-8-29, Musashidai, Fuchu, Tokyo, 183-8524, Japan

    Masataka Ogiso, Toshiaki Isogai, Ken Kato, Hiroyuki Tanaka & Tamotsu Tejima

  2. Department of Neurology, Tokyo Metropolitan Neurological Hospital, 2-6-1, Musashidai, Fuchu, Tokyo, 183-0042, Japan

    Eiji Isozaki

Authors
  1. Masataka Ogiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiaki Isogai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyuki Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamotsu Tejima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eiji Isozaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masataka Ogiso.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogiso, M., Isogai, T., Kato, K. et al. Electrocardiographic and echocardiographic findings in muscular dystrophy patients with heart failure. Heart Vessels 33, 1576–1583 (2018). https://doi.org/10.1007/s00380-018-1186-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00380-018-1186-5

Keywords

Search

Navigation